4/19
06:01 pm
rani
BGC, DRS and AMTX are among after hour movers [Seeking Alpha]
Medium
Report
BGC, DRS and AMTX are among after hour movers [Seeking Alpha]
3/27
08:07 am
rani
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $21.00 to $9.00. They now have a "buy" rating on the stock.
Low
Report
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $21.00 to $9.00. They now have a "buy" rating on the stock.
3/25
08:07 am
rani
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its price target lowered by analysts at HC Wainwright from $16.00 to $12.00. They now have a "buy" rating on the stock.
Low
Report
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its price target lowered by analysts at HC Wainwright from $16.00 to $12.00. They now have a "buy" rating on the stock.
3/21
10:01 am
rani
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/20
04:16 pm
rani
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update [Yahoo! Finance]
Medium
Report
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update [Yahoo! Finance]
3/20
04:05 pm
rani
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update
Low
Report
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update
3/15
04:20 pm
rani
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Low
Report
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
3/15
04:05 pm
rani
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
Low
Report
Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
3/12
06:42 am
rani
Individual investors own 40% of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shares but private companies control 47% of the company [Yahoo! Finance]
High
Report
Individual investors own 40% of Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) shares but private companies control 47% of the company [Yahoo! Finance]
2/6
09:31 am
rani
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $8.00 price target on the stock.
Low
Report
Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $8.00 price target on the stock.
2/5
08:12 am
rani
Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) [Yahoo! Finance]
High
Report
Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111) [Yahoo! Finance]
2/5
08:00 am
rani
Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111)
Medium
Report
Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111)